Published in Neurobiol Dis on July 25, 2009
Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat (2011) 1.85
Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol (2015) 0.86
Nur transcription factors in stress and addiction. Front Mol Neurosci (2013) 0.83
Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat (2013) 0.82
Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord (2014) 0.81
Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia. Eur J Neurosci (2013) 0.78
Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Biol Chem (2013) 0.77
A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES. J Histochem Cytochem (1964) 10.70
Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci (2006) 3.87
Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell (1995) 3.70
Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science (2000) 2.90
The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature (1984) 2.22
Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc Natl Acad Sci U S A (1978) 2.02
Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res (1988) 1.78
Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res Mol Brain Res (1996) 1.70
Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol (1999) 1.68
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci (2007) 1.61
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis (1999) 1.57
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry (2005) 1.53
Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc Natl Acad Sci U S A (1987) 1.40
Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci (2000) 1.39
Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol Endocrinol (1996) 1.31
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci (1996) 1.20
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci (1991) 1.15
Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism. Eur J Neurosci (2008) 1.14
Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 (NGFI-B) in adult rat brain using in situ hybridization. Neuroscience (1996) 1.12
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis (2004) 1.07
Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord (2008) 1.06
Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci (2006) 1.04
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol (2005) 1.03
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci (2005) 1.01
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol (2003) 0.99
Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J Neurochem (2000) 0.91
Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease. J Neurochem (2005) 0.90
Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm (Vienna) (2004) 0.90
Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry (2004) 0.90
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol (2006) 0.89
The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology (2004) 0.89
Pathophysiology of L-dopa-induced dyskinesias. Mov Disord (1999) 0.88
Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol Dis (2005) 0.88
Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci (2000) 0.87
The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis. Neuroscience (1995) 0.87
Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiol Dis (2005) 0.86
Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience (2001) 0.84
Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats. Neurobiol Dis (2003) 0.83
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. Eur J Neurosci (2006) 0.82
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord (2006) 0.79
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord (2003) 0.78
Subthalamotomy in the treatment of Parkinson's disease: clinical aspects and mechanisms of action. J Neurosurg (2013) 1.98
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci (2009) 1.89
Flexible ultrasonic transducers. IEEE Trans Ultrason Ferroelectr Freq Control (2006) 1.72
The dual dopamine-glutamate phenotype of growing mesencephalic neurons regresses in mature rat brain. J Comp Neurol (2009) 1.55
Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol (2009) 1.37
Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J (2004) 1.12
Contribution of spinal 5-HT1A and 5-HT7 receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice. Eur J Neurosci (2006) 1.12
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord (2011) 1.10
Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol Pharmacol (2006) 1.09
Defective dentate nucleus GABA receptors in essential tremor. Brain (2011) 1.07
Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol (2008) 1.05
Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci (2006) 1.04
Enhanced sucrose and cocaine self-administration and cue-induced drug seeking after loss of VGLUT2 in midbrain dopamine neurons in mice. J Neurosci (2011) 1.04
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem (2009) 1.03
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol (2005) 1.03
Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology (2007) 1.02
Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection. Eur J Neurosci (2008) 1.02
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain (2004) 1.02
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis (2003) 1.01
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.01
Induction patterns of transcription factors of the nur family (nurr1, nur77, and nor-1) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. J Pharmacol Exp Ther (2004) 1.01
Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia (2011) 0.99
ERbeta mediates the estradiol increase of D2 receptors in rat striatum and nucleus accumbens. Neuropharmacology (2005) 0.95
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging (2007) 0.93
Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology (2004) 0.92
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology (2010) 0.92
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord (2003) 0.92
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int (2006) 0.92
Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci (2002) 0.92
Opioids and motor complications in Parkinson's disease. Trends Pharmacol Sci (2006) 0.91
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis (2004) 0.91
Experimental validation of an optimized signal processing method to handle non-linearity in swept-source optical coherence tomography. Opt Express (2010) 0.90
Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease. J Neurochem (2005) 0.90
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res (2007) 0.90
Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry (2004) 0.90
The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology (2004) 0.89
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol (2006) 0.89
Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging (2006) 0.89
Clozapine and dopamine D3 receptor antisense reduce cocaine- and amphetamine-regulated transcript expression in the rat nucleus accumbens shell. Synapse (2004) 0.89
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord (2013) 0.88
Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. Eur J Neurosci (2004) 0.88
Neurochemical characterization of dopaminergic neurons in human striatum. Parkinsonism Relat Disord (2005) 0.88
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol (2002) 0.88
Chronic estrogenic drug treatment increases preproenkephalin mRNA levels in the rat striatum and nucleus accumbens. Psychoneuroendocrinology (2005) 0.87
Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology (2002) 0.87
Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J Neurochem (2010) 0.87
Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology (2011) 0.87
Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther (2010) 0.86
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. Mov Disord (2005) 0.86
Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiol Dis (2005) 0.86
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.85
Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover. Biol Psychiatry (2006) 0.85
Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord (2004) 0.85
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology (2003) 0.84
Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. Front Neuroendocrinol (2012) 0.83
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse (2006) 0.83
Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats. Neurobiol Dis (2003) 0.83
Relevance of animal models to human tardive dyskinesia. Behav Brain Funct (2012) 0.83
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging (2009) 0.82
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord (2009) 0.82
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. Eur J Neurosci (2006) 0.82
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.82
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology (2009) 0.82
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology (2013) 0.82